Merus (NASDAQ:MRUS) Shares Purchased by Wexford Capital LP

Wexford Capital LP boosted its position in Merus (NASDAQ:MRUS - Free Report) by 26.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 40,386 shares of the biotechnology company's stock after purchasing an additional 8,386 shares during the period. Wexford Capital LP owned about 0.06% of Merus worth $1,698,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. KBC Group NV lifted its position in Merus by 4,583.6% in the fourth quarter. KBC Group NV now owns 57,234 shares of the biotechnology company's stock valued at $2,407,000 after purchasing an additional 56,012 shares during the period. State of New Jersey Common Pension Fund D lifted its position in Merus by 29.0% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 48,268 shares of the biotechnology company's stock valued at $2,030,000 after purchasing an additional 10,842 shares during the period. Raymond James Financial Inc. acquired a new stake in Merus in the fourth quarter valued at about $347,000. Wells Fargo & Company MN lifted its position in Merus by 27.3% in the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock valued at $59,000 after purchasing an additional 300 shares during the period. Finally, Swiss National Bank lifted its position in Merus by 9.7% in the fourth quarter. Swiss National Bank now owns 93,954 shares of the biotechnology company's stock valued at $3,951,000 after purchasing an additional 8,300 shares during the period. Institutional investors and hedge funds own 96.14% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on MRUS shares. Wells Fargo & Company dropped their target price on shares of Merus from $91.00 to $89.00 and set an "overweight" rating for the company in a report on Thursday, May 8th. William Blair reaffirmed an "outperform" rating on shares of Merus in a report on Monday, April 28th. Bank of America dropped their target price on shares of Merus from $73.00 to $70.00 and set a "buy" rating for the company in a report on Monday, March 10th. Piper Sandler started coverage on shares of Merus in a report on Thursday, February 13th. They issued an "overweight" rating and a $84.00 target price for the company. Finally, Guggenheim reaffirmed a "buy" rating and issued a $109.00 target price on shares of Merus in a report on Friday, March 28th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $85.15.

Merus Stock Performance

Shares of MRUS opened at $41.56 on Monday. The stock has a fifty day moving average of $42.96 and a two-hundred day moving average of $43.66. The company has a market capitalization of $2.88 billion, a PE ratio of -10.52 and a beta of 0.94. Merus has a fifty-two week low of $33.19 and a fifty-two week high of $61.61.

Merus (NASDAQ:MRUS - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($1.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.23). Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. The company had revenue of $26.49 million for the quarter, compared to analysts' expectations of $7.82 million. As a group, equities research analysts forecast that Merus will post -3.85 earnings per share for the current fiscal year.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.